Is Kodak having a "Kodak moment?" 2 watchlist stocks.

Kodak's latest-quarter revenue rose 18% year over year to $311 million, with print revenue up 10% to $195 million and Advanced Materials & Chemicals revenue up 40% to $105 million. Gross margin expanded 700bps to 26% and operational EBITDA increased to $36 million from $9 million, but free cash flow was slightly negative at approximately $1 million; the analyst remains Neutral pending more consistent execution. NeurAxis revenue more than doubled to $1.9 million and pricing increased 28%, but its operating loss widened to $2.1 million and its roughly 12x TTM EV/sales valuation, limited operating leverage, and ATM dilution support a Neutral stance.

Analysis

KODK's valuation case hinges on whether the margin step-up reflects durable mix/pricing rather than a volatile quarter in a legacy manufacturing base. The important confirmation is cash conversion: sustained EBITDA without positive working-capital-adjusted free cash flow would imply capex, inventory, or receivables are absorbing the apparent turnaround. Its advanced-materials optionality should receive little standalone value until management discloses customer commitments, plant economics, and required capital; patent count is not a monetization metric. Over the next 1-3 months, another quarter of print stability and positive FCF could drive a rerating, but a reversal in gross margin or renewed cash burn would quickly restore the distressed-legacy multiple.

NRXS has a more binary setup. High gross margin and realized price increases are insufficient if commercial spend continues to rise faster than reimbursement-enabled procedure volume; the relevant inflection is sales-and-marketing efficiency and a narrowing loss, not headline revenue growth. Its small scale and ATM financing make dilution a structural offset to operating progress over 6-18 months, while liquidity can amplify both earnings upside and downside. Reimbursement expansion is the key catalyst, but payer coverage does not automatically translate into utilization; physician adoption and prior-authorization friction are the missing data.

Contrarianly, neither name is a clean read-through for broad EV, pharma, or medtech exposure. KODK's new-market narrative carries execution and capital-intensity risk, while NRXS's valuation already embeds substantial growth despite an unproven path to operating leverage. This is watchlist-quality news rather than a portfolio-level catalyst absent independent verification in filings and the next earnings prints.

Key Decisions for Investors

• Remain flat KODK ahead of the next quarterly filing; upgrade to a small long only if EBITDA remains above a $120m annualized pace and trailing two-quarter free cash flow turns positive. Risk is a margin normalization or working-capital reversal; invalidate the thesis on renewed negative FCF despite reported EBITDA growth.
• Set a KODK alert for disclosed binding advanced-materials customer contracts, project capex, and expected returns. Treat any share-price move driven solely by EV-battery or pharma-reagent narrative as fadeable until these data establish monetizable demand.
• Avoid initiating NRXS at the current revenue multiple. Reassess after two quarters only if revenue growth is accompanied by sequential operating-loss improvement and no material ATM dilution; a position would be a high-volatility, small-size event trade rather than a core healthcare long.
• For healthcare exposure, prefer profitable neuromodulation/medical-device comparables over NRXS until reimbursement-to-utilization conversion is demonstrated; monitor payer wins, procedure volumes, sales-force productivity, cash runway, and share count as the decisive quarterly metrics.